Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI-TL: HAIC + Tislelizumab + Lenvatinib for HCC with PVTT
NCT06210334Phase 2Not yet recruiting
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in hepatocellular carcinoma (HCC). Planned start Mar 2024; status: not yet recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06210334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06210334.